| Literature DB >> 34017124 |
Raoul J P Bonnal1,2, Grazisa Rossetti1,2, Enrico Lugli3,4, Marco De Simone1,5, Paola Gruarin1, Jolanda Brummelman3, Lorenzo Drufuca1,2, Marco Passaro1,2, Ramona Bason1,2, Federica Gervasoni1,2, Giulia Della Chiara1,2, Claudia D'Oria1,2, Martina Martinovic1, Serena Curti1, Valeria Ranzani1, Chiara Cordiglieri1, Giorgia Alvisi3, Emilia Maria Cristina Mazza3, Stefania Oliveto1, Ylenia Silvestri1, Elena Carelli1, Saveria Mazzara6, Roberto Bosotti1, Maria Lucia Sarnicola1, Chiara Godano1, Valeria Bevilacqua1, Mariangela Lorenzo1, Salvatore Siena7,8, Emanuela Bonoldi9, Andrea Sartore-Bianchi7,8, Alessio Amatu7, Giulia Veronesi10,11, Pierluigi Novellis11, Marco Alloisio12,13, Alessandro Giani14, Nicola Zucchini15, Enrico Opocher16,17, Andrea Pisani Ceretti16, Nicolò Mariani16, Stefano Biffo1,18, Daniele Prati19, Alberto Bardelli20,21, Jens Geginat22,23, Antonio Lanzavecchia24, Sergio Abrignani25,26, Massimiliano Pagani27,28,29.
Abstract
Regulatory T (Treg) cells are a barrier for tumor immunity and a target for immunotherapy. Using single-cell transcriptomics, we found that CD4+ T cells infiltrating primary and metastatic colorectal cancer and non-small-cell lung cancer are highly enriched for two subsets of comparable size and suppressor function comprising forkhead box protein P3+ Treg and eomesodermin homolog (EOMES)+ type 1 regulatory T (Tr1)-like cells also expressing granzyme K and chitinase-3-like protein 2. EOMES+ Tr1-like cells, but not Treg cells, were clonally related to effector T cells and were clonally expanded in primary and metastatic tumors, which is consistent with their proliferation and differentiation in situ. Using chitinase-3-like protein 2 as a subset signature, we found that the EOMES+ Tr1-like subset correlates with disease progression but is also associated with response to programmed cell death protein 1-targeted immunotherapy. Collectively, these findings highlight the heterogeneity of Treg cells that accumulate in primary tumors and metastases and identify a new prospective target for cancer immunotherapy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34017124 DOI: 10.1038/s41590-021-00930-4
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606